Arun Bhatt
Research Subjects
Research Interests
Arun Bhatt has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Deepa Chodankar
Medical Director, Syneos, GA, USA
1 shared publicationSanish Davis
Indian Society for Clinical Research, Mumbai, Maharashtra, India
1 shared publication
Latest Publications
- Open Access
- 15 October 2026
- Published by Wolters Kluwer Health in Perspectives in Clinical Research
- Vol. 17 (4) , 235-238
Authoring a literature review article: The prewriting QUEST of a beginner!
Clinical research professionals, skilled in medical writing, verbal communication, and presentations, are keen to become authors of a review article. They are not aware of the challenging prewriting process of meticulous planning, critical appraisal of the literature, brainstorming to select a topic, and structuring the article. Prewriting journey of acquiring knowledge and skills is discussed here briefly.
- 15 October 2026
- Published by Wolters Kluwer Health in Perspectives in Clinical Research
- Vol. 17 (4) , 235-238
Open AccessAuthoring a literature review article: The prewriting QUEST of a beginner!
Clinical research professionals, skilled in medical writing, verbal communication, and presentations, are keen to become authors of a review article. They are not aware of the challenging prewriting process of meticulous planning, critical appraisal of the literature, brainstorming to select a topic, and structuring the article. Prewriting journey of acquiring knowledge and skills is discussed here briefly.
- Open Access
- 13 April 2026
- Published by Wolters Kluwer Health in Perspectives in Clinical Research
- Vol. 17 (2) , 55-57
Ethics review of digital health research: Rethinking rights of participants
- 13 April 2026
- Published by Wolters Kluwer Health in Perspectives in Clinical Research
- Vol. 17 (2) , 55-57
Open AccessEthics review of digital health research: Rethinking rights of participants
- Open Access
- 20 February 2026
- Published by Wolters Kluwer Health in Perspectives in Clinical Research
- Vol. 17 (3) , 167-170
Quality of real-world registry studies
Registry studies are types of real-world studies (RWS), which are used to generate clinical evidence regarding therapeutic use, potential benefits, or risks of a medical product in real-world medical practice, and to support regulatory decisions. RWS are conducted using real-world data (RWD), which are collected for patient care management, but not collected in compliance with good clinical practice standards for documentation. Hence, ensuring data quality, integrity, and reliability for studies using RWD is difficult. It is important to ensure the quality of research, data, and evidence during the planning and conduct of registry studies. This brief review discusses the elements critical to ensuring quality during planning and reporting of RWS.
- 20 February 2026
- Published by Wolters Kluwer Health in Perspectives in Clinical Research
- Vol. 17 (3) , 167-170
Open AccessQuality of real-world registry studies
Registry studies are types of real-world studies (RWS), which are used to generate clinical evidence regarding therapeutic use, potential benefits, or risks of a medical product in real-world medical practice, and to support regulatory decisions. RWS are conducted using real-world data (RWD), which are collected for patient care management, but not collected in compliance with good clinical practice standards for documentation. Hence, ensuring data quality, integrity, and reliability for studies using RWD is difficult. It is important to ensure the quality of research, data, and evidence during the planning and conduct of registry studies. This brief review discusses the elements critical to ensuring quality during planning and reporting of RWS.
- Open Access
- 22 January 2026
- Published by Wolters Kluwer Health in Perspectives in Clinical Research
- Vol. 17 (1) , 1-3
Renaissance of Phase I trials in India: Lessons from global trials and tribulations of TGN1412
- 22 January 2026
- Published by Wolters Kluwer Health in Perspectives in Clinical Research
- Vol. 17 (1) , 1-3
Open AccessRenaissance of Phase I trials in India: Lessons from global trials and tribulations of TGN1412
- Open Access
- 26 September 2025
- Published by Wolters Kluwer Health in Perspectives in Clinical Research
- Vol. 17 (2) , 65-70
Clinical research in pediatric population: Scientific and ethical aspects
Children are a unique population with important differences in physical, physiological, and emotional differences from adults. Hence, research outcomes of studies conducted in adults cannot be extrapolated to pediatric population. However, there is scarcity of data on the safety and efficacy of new interventions in children, due to concerns about risks of research in children. It is vital to conduct scientifically robust and ethically sound observational noninterventional studies and interventional therapy clinical trials in children to provide supporting evidence for medical practices in the pediatric population, to advance understanding of diseases, and to provide quality health care. This is a brief review of scientific and ethical considerations in planning and conduct of clinical research in children.
- 26 September 2025
- Published by Wolters Kluwer Health in Perspectives in Clinical Research
- Vol. 17 (2) , 65-70
Open AccessClinical research in pediatric population: Scientific and ethical aspects
Children are a unique population with important differences in physical, physiological, and emotional differences from adults. Hence, research outcomes of studies conducted in adults cannot be extrapolated to pediatric population. However, there is scarcity of data on the safety and efficacy of new interventions in children, due to concerns about risks of research in children. It is vital to conduct scientifically robust and ethically sound observational noninterventional studies and interventional therapy clinical trials in children to provide supporting evidence for medical practices in the pediatric population, to advance understanding of diseases, and to provide quality health care. This is a brief review of scientific and ethical considerations in planning and conduct of clinical research in children.
- Open Access
- 27 May 2025
- Published by Wolters Kluwer Health in Perspectives in Clinical Research
- Vol. 16 (3) , 127-131
Applied intelligence in clinical drug development: Potential benefits and emerging concerns
The use of artificial intelligence (AI) technology and machine learning (ML) is growing exponentially and is moving from AI to applied intelligence. Pharma industry is actively exploring the potential use of AI tools in new product discovery and clinical development. Some of the practical applications of AI in clinical development are for improving the efficiency of enrollment, selection and stratification of participants, optimizing study treatment, enhancing compliance, data analysis, and pharmacovigilance. AI applications have been used for outcome prediction; covariate selection/confounding adjustment; anomaly detection; real-world data phenotyping; imaging, video, and voice analysis; endpoint assessment; and pharmacometric modeling in regulatory submissions. However, widespread applications of novel yet difficult-to-understand AI technology in clinical development would need balancing the benefits and risks and resolving issues of scientific validity, technical quality, and ethics. The article discusses the potential benefits and emerging concerns of applying AI in clinical drug development.
- 27 May 2025
- Published by Wolters Kluwer Health in Perspectives in Clinical Research
- Vol. 16 (3) , 127-131
Open AccessApplied intelligence in clinical drug development: Potential benefits and emerging concerns
The use of artificial intelligence (AI) technology and machine learning (ML) is growing exponentially and is moving from AI to applied intelligence. Pharma industry is actively exploring the potential use of AI tools in new product discovery and clinical development. Some of the practical applications of AI in clinical development are for improving the efficiency of enrollment, selection and stratification of participants, optimizing study treatment, enhancing compliance, data analysis, and pharmacovigilance. AI applications have been used for outcome prediction; covariate selection/confounding adjustment; anomaly detection; real-world data phenotyping; imaging, video, and voice analysis; endpoint assessment; and pharmacometric modeling in regulatory submissions. However, widespread applications of novel yet difficult-to-understand AI technology in clinical development would need balancing the benefits and risks and resolving issues of scientific validity, technical quality, and ethics. The article discusses the potential benefits and emerging concerns of applying AI in clinical drug development.
- Open Access
- 4 July 2024
- Published by Medknow in Perspectives in Clinical Research
- Vol. 15 (3) , 122-127
Bio-entrepreneurs’ bugbear: Regulatory rigmarole
Indian biotech startup sector – a rapidly growing business segment focused on the development of innovative products has the potential to make significant contributions to the country’s economy. Indian bio-entrepreneurs’ optimistic expectation of rapidly moving product development from bench to bedside faces tremendous challenges of the complex Indian regulatory system, which is shaped by a diversity of regulatory authorities, rules, guidelines, and processes. This brief review discusses specific regulatory issues faced by bio-entrepreneurs investing in a variety of innovative products – new drugs, vaccines, medical devices, cell, and gene therapy and suggests approaches which can ease Indian entrepreneur’s endeavors.
- 4 July 2024
- Published by Medknow in Perspectives in Clinical Research
- Vol. 15 (3) , 122-127
Open AccessBio-entrepreneurs’ bugbear: Regulatory rigmarole
Indian biotech startup sector – a rapidly growing business segment focused on the development of innovative products has the potential to make significant contributions to the country’s economy. Indian bio-entrepreneurs’ optimistic expectation of rapidly moving product development from bench to bedside faces tremendous challenges of the complex Indian regulatory system, which is shaped by a diversity of regulatory authorities, rules, guidelines, and processes. This brief review discusses specific regulatory issues faced by bio-entrepreneurs investing in a variety of innovative products – new drugs, vaccines, medical devices, cell, and gene therapy and suggests approaches which can ease Indian entrepreneur’s endeavors.
- Open Access
- 22 February 2024
- Published by Medknow in Perspectives in Clinical Research
- Vol. 15 (3) , 152-154
Ethical considerations for real-world evidence studies
Real-world evidence (RWE) studies are conducted on patient’s data primarily collected for monitoring of health status of patients. The use of real-world data to generate evidence in academic research or for regulatory submission raises a variety of ethical issues such as privacy, confidentiality, data protection, data de-identification, data sharing, scientific design of study, and informed consent requirements. The investigators–researchers and sponsors should adhere to current standards of ethics whilst planning and conduct of RWE studies. The ethics committees should consider ethical issues specific to RWE studies before approval.
- 22 February 2024
- Published by Medknow in Perspectives in Clinical Research
- Vol. 15 (3) , 152-154
Open AccessEthical considerations for real-world evidence studies
Real-world evidence (RWE) studies are conducted on patient’s data primarily collected for monitoring of health status of patients. The use of real-world data to generate evidence in academic research or for regulatory submission raises a variety of ethical issues such as privacy, confidentiality, data protection, data de-identification, data sharing, scientific design of study, and informed consent requirements. The investigators–researchers and sponsors should adhere to current standards of ethics whilst planning and conduct of RWE studies. The ethics committees should consider ethical issues specific to RWE studies before approval.
- Open Access
- 5 October 2023
- Published by Medknow in Perspectives in Clinical Research
- Vol. 14 (4) , 167-171
The revamped Good Clinical Practice E6(R3) guideline: Profound changes in principles and practice!
The International Council for Harmonisation has released a draft version E6(R3) of the Good Clinical Practice Guideline for public consultation. The objective of the revamped guideline is to make the new provisions applicable across diverse clinical trial types and settings and to remain relevant as technological and methodological advances occur. E6(R3) includes profound changes in the structure and content of E6(R2) version, which will impact all the trial conduct processes from planning to reporting. This guideline’s focus on principles, digital technology, ethics, and quality will increase the responsibilities of the ethics committees, the investigator, and the sponsor. This brief review discusses the impact of the guideline on trial conduct and the challenges of implementation in India.
- 5 October 2023
- Published by Medknow in Perspectives in Clinical Research
- Vol. 14 (4) , 167-171
Open AccessThe revamped Good Clinical Practice E6(R3) guideline: Profound changes in principles and practice!
The International Council for Harmonisation has released a draft version E6(R3) of the Good Clinical Practice Guideline for public consultation. The objective of the revamped guideline is to make the new provisions applicable across diverse clinical trial types and settings and to remain relevant as technological and methodological advances occur. E6(R3) includes profound changes in the structure and content of E6(R2) version, which will impact all the trial conduct processes from planning to reporting. This guideline’s focus on principles, digital technology, ethics, and quality will increase the responsibilities of the ethics committees, the investigator, and the sponsor. This brief review discusses the impact of the guideline on trial conduct and the challenges of implementation in India.
- Open Access
- 13 April 2023
- Published by Medknow in Perspectives in Clinical Research
- Vol. 14 (2) , 92-94
Data quality – The foundation of real-world studies
Real-world data, routinely collected from multiple sources outside typical clinical research settings, are useful in conducting real-world studies. Sub-optimal and inconsistent data quality is a challenging issue which should be addressed whilst planning and conducting real-world studies. This brief review discusses the quality aspects of data needed for RWS.
- 13 April 2023
- Published by Medknow in Perspectives in Clinical Research
- Vol. 14 (2) , 92-94
Open AccessData quality – The foundation of real-world studies
Real-world data, routinely collected from multiple sources outside typical clinical research settings, are useful in conducting real-world studies. Sub-optimal and inconsistent data quality is a challenging issue which should be addressed whilst planning and conducting real-world studies. This brief review discusses the quality aspects of data needed for RWS.